Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.40 |
| ▸ | PIK3R2 | O00459 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754242 | 0.90 | CNR1 (0.43) | CNR1ADORA2ACNR2 | |
| SCHEMBL1754134 | 0.88 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL1753989 | 0.86 | CNR1 (0.42) | CNR1PIK3CDPIK3CGADORA2APIK3R1 | |
| SCHEMBL2087359 | 0.81 | MAP4K4 (0.42) | — | |
| SCHEMBL2083247 | 0.80 | CNR1 (0.40) | CNR1PIK3CDPIK3CGPIK3R2ADORA2A | |
| SCHEMBL13571650 | 0.79 | CNR1 (0.37) | CNR1PIK3CDPIK3CGPIK3R2ADORA2A | |
| SCHEMBL1754327 | 0.78 | CNR1 (0.37) | CNR1ADORA2ABTKCNR2 | |
| SCHEMBL2083585 | 0.78 | GPR119 (0.45) | — | |
| SCHEMBL1754467 | 0.77 | MAPT (0.35) | CNR1CNR2 | |
| SCHEMBL1753993 | 0.76 | CNR1 (0.40) | CNR1PIK3CDPIK3CGADORA2APIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2035427-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | CNR1 1/4885PIK3CD 1369/4885PIK3CG 1195/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | CNR1 1/4885PIK3CD 1587/4885PIK3CG 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.